What is HC Wainwright’s Estimate for Immunocore Q1 Earnings?

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Immunocore in a report issued on Wednesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.26) per share for the quarter, up from their prior forecast of ($0.28). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($1.35) EPS.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, February 25th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.32). Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The business had revenue of $104.48 million for the quarter, compared to analyst estimates of $145.48 million. During the same period in the prior year, the business earned ($0.47) EPS. The company’s revenue for the quarter was up 24.3% on a year-over-year basis.

Several other brokerages have also issued reports on IMCR. UBS Group set a $55.00 target price on shares of Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. Morgan Stanley raised their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Mizuho set a $38.00 target price on Immunocore in a research report on Thursday, February 19th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $61.30.

Immunocore Stock Performance

Shares of IMCR stock opened at $31.93 on Friday. The firm has a 50 day moving average of $33.17 and a 200-day moving average of $34.32. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -45.61 and a beta of 0.78. The company has a quick ratio of 4.01, a current ratio of 4.04 and a debt-to-equity ratio of 1.03. Immunocore has a 52 week low of $23.15 and a 52 week high of $40.71.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMCR. GAMMA Investing LLC boosted its holdings in Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the last quarter. Harbour Investments Inc. lifted its position in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after buying an additional 388 shares in the last quarter. DNB Asset Management AS boosted its stake in shares of Immunocore by 6.4% in the 3rd quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock worth $295,000 after buying an additional 488 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after acquiring an additional 572 shares in the last quarter. Finally, R Squared Ltd raised its stake in shares of Immunocore by 7.4% during the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after purchasing an additional 606 shares during the period. 84.50% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Bahija Jallal sold 11,474 shares of Immunocore stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer owned 12,343 shares of the company’s stock, valued at $399,296.05. The trade was a 48.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David M. Berman sold 5,965 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $192,967.75. Following the completion of the sale, the insider directly owned 5,859 shares of the company’s stock, valued at $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,137 shares of company stock worth $619,082 over the last 90 days. 10.40% of the stock is currently owned by corporate insiders.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.